Ibico

Mebeverine Hydrochloride, the active ingredient in Ibico, is an antispasmodic presented as an oral formulation for oral use. It helps improve bowel habit regularity and reduces abdominal discomfort by relieving gastrointestinal smooth‑muscle spasms associated with irritable bowel syndrome and other functional bowel disorders.

GNH USA supplies Ibico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation to support global distribution. Ibico is manufactured under EU Good Manufacturing Practice guidelines to ensure consistent purity and potency.

Mebeverine Hydrochloride acts on gastrointestinal smooth muscle to alleviate spasm in several functional bowel conditions.

- Irritable bowel syndrome: reduces abdominal pain, cramping and improves stool consistency. - Functional bowel disorders: eases irregular bowel movements and decreases discomfort. - Spastic colon: relaxes colonic muscle tone, helping to normalize transit.

Mebeverine Hydrochloride is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Nausea: mild stomach upset. - Dry mouth: reduced salivation. - Headache: transient head pain. - Dizziness: light‑headed sensation. - Abdominal discomfort: mild cramps.

Serious or Rare Side Effects: - Allergic reaction: rash, itching or swelling. - Angioedema: swelling of face, lips or throat. - Severe cardiac arrhythmia: irregular heartbeat (very rare).

When prescribing Mebeverine Hydrochloride, consider the following precautions to ensure safe use.

- Assess renal function: adjust use in severe renal impairment. - Monitor hepatic function: use cautiously in liver disease. - Observe for allergic reactions: discontinue if rash or swelling occurs. - Avoid in known hypersensitivity: do not prescribe to patients with previous mebeverine allergy. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mebeverine Hydrochloride may interact with other medicines; awareness of these interactions helps prevent adverse effects.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors: may increase mebeverine plasma concentrations. - Concomitant antispasmodics: risk of additive gastrointestinal relaxation.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may enhance dry‑mouth effect. - Tricyclic antidepressants: increased anticholinergic burden. - Diuretics: monitor electrolyte balance when combined.